Document:

Exhibit
4.1

 

DESCRIPTION
OF THE REGISTRANT’S SECURITIES

 

REGISTERED
PURSUANT TO SECTION 12 OF THE

 

SECURITIES
EXCHANGE ACT OF 1934

 

As
of September 28, 2020, Genetic Technologies Limited (the “Company”) has one class of its securities, American depositary
shares (“ADS”), registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”).

 

The
following description of our ADS is a summary and is subject to, and is qualified in its entirety by reference to, the provisions
of our Constitution, a copy of which is incorporated by reference as Exhibits 3.1, to our Registration Statement on Form 20-F
filed with the Commission on December 21, 2010.

 

ADS

 

The
Bank of New York Mellon, as depositary, will register and deliver ADSs. Each ADS represents six hundred ordinary shares (or a
right to receive six hundred ordinary shares) deposited with HSBC Bank Australia Limited, as custodian for the depositary. Each
ADS also represents any other securities, cash or other property which may be held by the depositary. The depositary’s corporate
trust office at which the ADSs are administered, and its executive offices, are located at 240 Greenwich Street, New York, New
York 10286.

 

You
may hold ADSs either (A) directly (i) by having an American depositary receipt, which is a certificate evidencing a specific number
of ADSs, registered in your name, or (ii) by holding ADSs in the Direct Registration System, or (B) indirectly through your broker
or other financial institution. If you hold ADSs directly, you are an ADS holder. This description assumes you hold the ADSs directly.
If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights
of ADR holders described in this section. You should consult with your broker or financial institution to find out what those
procedures are.

 

The
Direct Registration System is a system administered by DTC pursuant to which the depositary may register the ownership of uncertificated
ADSs, which ownership shall be confirmed by periodic statements issued by the depositary to the ADS holders entitled thereto.

 

As
an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Australian law governs
shareholder rights. The depositary will be the holder of the shares underlying the ADSs. As a holder of ADSs, you will have ADS
holder rights. A deposit agreement among us, the depositary and you, as an ADS holder, and the beneficial owners of ADSs set out
ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the
ADSs.

 

The
following is a summary of the material provisions of the deposit agreement.

 

Dividends
and Other Distributions

 

In
the event that we pay a cash dividend or make another distribution, the depositary has agreed to pay to you the cash dividends
or other distributions it or the custodian receives on shares or other deposited securities, after deducting its fees and expenses.
You will receive these distributions in proportion to the number of shares the ADSs represent.

 

	 	●	Cash.
    The depositary will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can
    do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government
    approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency
    only to those ADR holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account
    of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest.

 

    	 	 	 

     

    

 

	 	● 	Before
    making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. The depositary
    will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If exchange
    rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value
    of the distribution.
	 	 	 
	 	●	Shares.
    The depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The
    depositary will only distribute whole ADSs. It will sell shares which would require it to deliver a fractional ADS and distribute
    the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding
    ADSs will also represent the new shares.
	 	 	 
	 	●	Rights
    to Purchase Additional Shares. If we offer holders of our securities any rights to subscribe for additional shares
    or any other rights, the depositary may make these rights available to you. If the depositary decides it is not legal and
    practical to make the rights available but that it is practical to sell the rights, the depositary will use reasonable efforts
    to sell the rights and distribute the proceeds in the same way as it does with cash. The depositary will allow rights that
    are not distributed or sold to lapse. In that case, you will receive no value for them.
	 	 	 
	 	●	If
    the depositary makes rights available to you, it will exercise the rights and purchase the shares on your behalf. The depositary
    will then deposit the shares and deliver ADSs to you. It will only exercise rights if you pay it the exercise price and any
    other charges the rights require you to pay.
	 	 	 
	 	●	U.S.
    securities laws may restrict transfers and cancellation of the ADSs represented by shares purchased upon exercise of rights.
    For example, you may not be able to trade these ADSs freely in the United States. In this case, the depositary may deliver
    restricted depositary shares that have the same terms as the ADSs described in this section except for changes needed to put
    the necessary restrictions in place.
	 	 	 
	 	●	Other
    Distributions. The depositary will send to you anything else we distribute on deposited securities by any means it thinks
    is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to
    sell what we distributed and distribute
	 	 	 
	 	●	the
    net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will
    also represent the newly distributed property. However, the depositary is not required to distribute any securities (other
    than ADSs) to you unless it receives satisfactory evidence from us that it is legal to make that distribution.

 

The
depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders.
We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation
to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that
you may not receive the distributions we make on our shares or any value for them if it is illegal or impractical for us to make
them available to you.

 

As
of September 28, 2020, our ADS was listed on the Nasdaq Capital Market under the symbol “GENE.”Exhibit 10.1

 

 

BACKSTOP AGREEMENT

 

This Backstop Agreement
(this “Agreement”) is made as of [____________], 2020 by and among (i) Tenzing Acquisition Corp.,
a company incorporated in the British Virgin Islands (together with its successors, including after the Conversion (as defined
below), the “Company”), (ii) Reviva Pharmaceuticals, Inc., a Delaware corporation (together with
its successors, “Reviva”), and (iii) [________________________], a [jurisdiction and type of entity]
(“Investor”), and is intended to set forth certain representations, covenants and agreements among the
Company, Reviva and Investor with respect to the acquisition by Investor of an aggregate of [___________________] (together with
any replacement shares of Common Stock (as defined bellow) after the Conversion, the “Subject Shares”)
ordinary shares, no par value, of the Company (“Ordinary Shares”) through the open market and private
transactions described in Section 3 hereof. The respective representations, warranties, covenants and agreements set forth
herein are made in connection with the Company’s proposed business combination with Reviva pursuant to that certain Agreement
and Plan of Merger, dated as of July 20, 2020 (as it may be amended, the “Merger Agreement”), by and
among (A) the Company, (B) Tenzing Merger Subsidiary Inc., a Delaware corporation and a wholly-owned subsidiary of the Company
(“Merger Sub”), (C) Tenzing LLC, a Delaware limited liability company (the “Sponsor”),
in its capacity as the Purchaser Representative thereunder, (D) Laxminarayan Bhat, in the capacity as the Seller Representative
thereunder, and (E) Reviva, pursuant to which Merger Agreement, upon the consummation of the transactions contemplated thereby
(the “Closing”), among other matters, (x) the Company will continue out of the British Virgin Islands
and into the State of Delaware so as to re-domicile as and become a Delaware corporation (the “Conversion”),
and (y) Merger Sub will merge with and into Reviva, with Reviva continuing as the surviving entity (the “Merger”),
and as a result of which, all of the issued and outstanding capital stock of Reviva immediately prior to the consummation of the
Merger shall no longer be outstanding and shall automatically be cancelled and shall cease to exist, in exchange for the right
to receive shares of common stock, par value $0.0001 per share, of the Company after the Conversion (“Common Stock”),
and with outstanding options and warrants of Reviva being assumed by the Company, in each case, subject to the terms and conditions
of the Merger Agreement (the Conversion, the Merger and the other transactions contemplated by the Merger Agreement, collectively,
the “Reviva Transaction”). Certain capitalized terms used in this Agreement are defined in Section
18 below.

 

1. Transfer Restrictions. Investor covenants and agrees that until the earlier of (i) the Closing or (ii) the
date on which the Merger Agreement is terminated in accordance with its terms, it shall not, and shall cause each of its Affiliate
to not, without the Company’s and Reviva’s prior written consent, (i) offer for sale, sell (including short sales),
transfer, tender, pledge, encumber, assign or otherwise dispose of (including by gift) (collectively, a “Transfer”),
or enter into any contract, option, derivative, hedging or other agreement or arrangement or understanding (including any profit-sharing
arrangement) with respect to, or consent to, a Transfer of, any or all of the Subject Shares that it acquires; (ii) grant any proxies
or powers of attorney with respect to any or all of the Subject Shares (other than as expressly contemplated by the definitive
proxy statement for the Merger Meeting or any definitive proxy statement for any Company shareholder meeting for an Extension);
(iii) permit to exist any lien of any nature whatsoever with respect to any or all of the Subject Shares; or (iv) take any action
that would have the effect of preventing, impeding, interfering with or adversely affecting Investor’s ability to perform
its obligations under this Agreement. Promptly following Investor’s acquisition of any Subject Shares, upon the Company’s
written request, Investor will advise the Company’s transfer agent in writing the Subject Shares are subject to the restrictions
set forth in this Agreement and, in connection therewith, provide the Company’s transfer agent in writing with such information
as is reasonable to ensure compliance with such restrictions. Nothing contained in this Agreement shall be deemed to vest in the
Company or Reviva any direct or indirect ownership or incidence of ownership of or with respect to any Subject Shares. If any Transfer
is made or attempted contrary to the provisions of this Section 1, such purported Transfer shall be null and void ab initio,
and the Company shall refuse to recognize any such purported transferee of the applicable Subject Shares as one of its equity holders
for any purpose. In order to enforce this Section 1, the Company may impose stop-transfer instructions with respect to Investor’s
Subject Shares until the end of the period required by this Section this Section 1.

 

     

     

    

 

2. Non-Redemption of Ordinary Shares.

 

(a) Investor covenants and agrees that it shall, and shall cause each of its Affiliates to, waive and not exercise any
rights that it may have to redeem or convert any Ordinary Shares that owns, including any Backstop Shares that it acquires under
Section 3, in connection with the redemption conducted by the Company in accordance with the Company’s organizational
documents and the IPO Prospectus (as defined below) in conjunction with the Reviva Transaction (the “Closing Redemption”).

 

(b) Investor further covenants and agrees that, in the event that prior to the Closing the Company seeks to amend its
organizational documents to extend the date by which the Company must complete its Business Combination (as defined below) (an
 “Extension”), Investor shall, and shall cause each of its Affiliates to waive and not exercise any rights
that it may have to redeem or convert any Ordinary Shares that it owns, including any Backstop Shares that it acquires under Section
3, in connection with the redemption conducted by the Company in accordance with the Company’s organizational documents
and the IPO Prospectus in conjunction with such Extension (an “Extension Redemption”).

 

3. Backstop. Commencing on the date hereof and through 5:00 p.m. Eastern Time on the last date on which it may
purchase Ordinary Shares (the “Market Deadline”) such that the settlement of such purchase shall occur
on or before the record date for the special meeting of shareholders (the “Merger Meeting”) to be held
by the Company to approve, among other things, the Merger Agreement and the Reviva Transaction, pursuant to a proxy statement to
be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) in connection with
the Merger Meeting (as supplemented by definitive additional materials filed with SEC, the “Reviva Proxy Statement”),
Investor shall (provided it is lawful to do so) use its best efforts to as promptly as practicable after the date hereof purchase
the Subject Shares in the open market (“Open Market Shares”) or in privately negotiated transactions
with third parties (“Private Purchase Shares” and, together with Open Market Shares, “Backstop
Shares”). Between the Market Deadline and through 5:00 p.m. Eastern Time on the last date on which it may purchase
Private Purchase Shares such that the settlement of such purchase shall occur on or before the close of business on the second
(2nd) Business Day prior to the Merger Meeting (the “Private Deadline”), to the extent that
Investor has not purchased all of the Subject Shares prior to the Market Deadline, Investor shall (provided it is lawful to do
so) use its best efforts to purchase as promptly as practicable after such date Private Purchase Shares in an aggregate amount
equal to the shortfall of Subject Shares that it failed to purchase prior to the Market Deadline, provided that Investor obtains
from such third parties irrevocable proxies with respect to the Merger Meeting (and if applicable, any Company shareholder meeting
for an Extension) and written waivers of their Closing Redemption rights (and any Extension Redemption rights, if applicable) with
respect to such Private Purchase Shares. On the day immediately following each of the Market Deadline and the Private Deadline,
and promptly at other times requested by the Company or Reviva from time to time, Investor shall (x) notify the Company and Reviva
in writing of the number of aggregate Backstop Shares purchased from the date of this Agreement through such applicable date, and
(y) provide the Company and Reviva, for all Backstop Shares acquired, all documentary evidence reasonably requested by or on behalf
of the Company or Reviva to confirm that Investor has purchased such Backstop Shares and holds such Backstop Shares through the
Merger Meeting and has not submitted any such Backstop Shares for the Closing Redemption or any Extension Redemption and has revoked
any prior redemption elections with respect to such Backstop Shares.

 

4. Additional Share Issuance. The Company hereby agrees that for each full ten (10) Backstop Shares that are
purchased by Investor on or prior to October 23, 2020, and that Investor holds without Transfer and does not redeem through the
Closing, in each case, in accordance with the requirements of this Agreement, and subject to Investor’s compliance in all
material respects with the other provisions of this Agreement and the consummation of the Closing, the Company shall, within ten
(10) Business Days following the Closing, issue to Investor one (1) share of Common Stock (such share of Common Stock, an “Additional
Share” and the Additional Shares collectively with the Backstop Shares, the “Shares”) (for
the avoidance of doubt, with no fractional Additional Shares will be issued and any fractional Additional Shares will be rounded
down to the nearest whole share).

 

    	 	2	 

     

    

 

5. Representations, Warranties, Understandings, Risk Acknowledgments, and Covenants of Investor. Investor hereby
represents, warrants and covenants to each of the Company and Reviva as follows:

 

(a) Investor will be purchasing the Subject Shares for its own account, not as a nominee or agent. Investor will not
sell, assign or transfer any Subject Shares at any time in violation of the Securities Act, or applicable state securities laws.
Investor acknowledges that the Additional Shares cannot be sold unless subsequently registered under the Securities Act and applicable
state securities laws or an exemption from such registration is available. Investor understands that the Additional Shares (i)
have not been (and upon their sale will not be) registered under the Securities Act or any state securities laws, (ii) have been
offered and will be sold in reliance upon an exemption from the registration and prospectus delivery requirements of the Securities
Act, and (iii) will be issued in reliance upon exemptions from the registration and prospectus delivery requirements of state securities
laws which relate to private offerings. Pursuant to the foregoing, Investor acknowledges that until such time as the resale of
the Additional Shares have been registered under the Securities Act or may otherwise may be sold pursuant to an exemption from
registration, any certificates representing any Additional Shares acquired by Investor shall bear a customary restrictive legend
(and a stop-transfer order may be placed against transfer of any certificates evidencing such Additional Shares) reflecting such
limitations in form and substance reasonably acceptable to the Company.

 

(b) Investor has knowledge, skill and experience in financial, business and investment matters relating to an investment
of this type and is capable of evaluating the merits and risks of such investment and protecting Investor’s interest in connection
with the acquisition of the Subject Shares. Investor understands that the acquisition of the Subject Shares is a speculative investment
and involves substantial risks and that Investor could lose its entire investment. Further, the undersigned has (i) carefully read
and considered the risks identified in the Disclosure Documents (as defined below) and (ii) carefully considered and understands
all of the risks related to the Reviva Transaction, the Company, Reviva, any Extension, the Subject Shares and this Agreement.
Acknowledging the very significant tax impact analysis and other analyses that is warranted in determining the consequences to
it of purchasing and owning the Subject Shares, to the extent deemed necessary by Investor, Investor has had the opportunity to
retain, at its own expense, and relied upon, appropriate professional advice regarding the investment, tax and legal merits and
consequences of the foregoing, including purchasing and owning the Subject Shares. Investor has the ability to bear the economic
risks of Investor’s investment in the Company, including a complete loss of the investment, and Investor has no need for
liquidity in such investment.

 

(c) Investor has been furnished by or on behalf of the Company all information (or provided access to all information
it reasonably requested) regarding the business and financial condition of the Company, Reviva, the expected plans for future business
activities, and the merits and risks of an investment in the Subject Shares which Investor has reasonably requested or otherwise
needs to evaluate the investment in the Subject Shares. Investor is in receipt of and has carefully read and understands the following
items (collectively, the “Disclosure Documents”): (i) the final prospectus of the Company, dated as of
August 20, 2018, and filed with the SEC on August 22, 2018 (File Nos. 333-226263 and 333-226952) (the “IPO Prospectus”);
(ii) each filing made by the Company with the SEC following the filing of the IPO Prospectus through the date of this Agreement;
(iii) the Merger Agreement, a copy of which has been filed by the Company with the SEC; and (iv) the investor presentation by the
Company and Reviva, a copy of which has been furnished by the Company with the SEC. Investor understands the significant extent
to which certain of the disclosures contained in items (i) and (ii) above shall no longer apply following the Closing. Investor
acknowledges that neither the Company, nor Reviva, nor any of their respective Representatives has made or makes any representation
or warranty to Investor in respect of the Company, Reviva, any Extension, the Reviva Transaction, the Subject Shares or this Agreement,
other than the representations and warranties contained in this Agreement. In making its investment decision to acquire the Subject
Shares, Investor is relying solely on investigations made by Investor and its Representatives.

 

    	 	3	 

     

    

 

(d)  Investor acknowledges that it has been advised that: (i) the Subject Shares have not been approved or disapproved
by the SEC or any state securities commission nor has the SEC or any state securities commission passed upon the accuracy or adequacy
of any representations by the Company, and any representation to the contrary is a criminal offense; (ii) in making an investment
decision, Investor must rely on its own examination of the Company, Reviva, the Reviva Transaction, any Extension and the Subject
Shares, including the merits and risks involved, the Subject Shares have not been recommended by any federal or state securities
commission or regulatory authority, and the foregoing authorities have not confirmed the accuracy or determined the adequacy of
any representation (and any representation to the contrary is a criminal offense); (iii) any Additional Shares will be “restricted
securities” within the meaning of Rule 144 under the Securities Act, are subject to restrictions on transferability and resale
and may not be transferred or resold except as permitted under the Securities Act and applicable state securities laws, pursuant
to registration or exemption therefrom. Investor is aware of the provisions of Rule 144 are not currently available and, in the
future, may not become available for resale of any of the Additional Shares and that the Company is an issuer subject to Rule 144(i)
under the Securities Act.

 

(e) Investor further represents and warrants that it is a “qualified institutional buyer” within the meaning
of Rule 144A under the Securities Act, or an “accredited investor” within the meaning of Rule 501 of Regulation D under
the Securities Act, and Investor has executed the Investor Questionnaire attached hereto as Exhibit A (the “Investor
Questionnaire”) and shall provide to the Company and Reviva an updated Investor Questionnaire for any change in circumstances
at any time on or prior to the Closing. As of the date of this Agreement, Investor and its Affiliates do not have, and during the
thirty (30) day period prior to the date of this Agreement, Investor and its Affiliates have not, in a seller, transferor or other
similar capacity, entered into, any “put equivalent position” as such term is defined in Rule 16a-1 of the Exchange
Act or short sale positions with respect to the securities of the Company. In addition, Investor shall comply with all applicable
provisions of Regulation M promulgated under the Securities Act.

 

(f) Investor has the full legal right and power and all authority and approval required (i) to execute and deliver, or
authorize execution and delivery of, this Agreement and all other instruments executed and delivered by or on behalf of Investor
in connection with the acquisition of the Subject Shares, (ii) to delegate authority pursuant to power of attorney and (iii) to
acquire and hold the Subject Shares. The signature of the person signing on behalf of Investor is binding upon Investor. Investor
has not been formed for the specific purpose of acquiring the Subject Shares unless each beneficial owner of Investor is a “qualified
institutional buyer” within the meaning of Rule 144A under the Securities Act, or is qualified as an accredited investor
within the meaning of Rule 501(a) of Regulation D promulgated under the Securities Act and has submitted information substantiating
such individual qualification. If Investor is a retirement plan or is investing on behalf of a retirement plan, Investor acknowledges
that investment in the Subject Shares poses additional risks including the inability to use losses generated by an investment in
the Subject Shares to offset taxable income. This Agreement has been duly authorized, executed and delivered by Investor and constitutes
a legal, valid and binding obligation of Investor enforceable against Investor in accordance with its terms, except as such enforceability
may be limited by: (i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws in effect that limit
creditors’ rights generally; (ii) equitable limitations on the availability of specific remedies; (iii) principles of equity
(regardless of whether such enforcement is considered in a proceeding in law or in equity); and (iv) to the extent rights to indemnification
and contribution may be limited by federal securities laws or the public policy underlying such laws.

 

    	 	4	 

     

    

 

(g) Investor understands and confirms that the Company and Reviva will rely on the representations and covenants contained
herein in effecting the transactions contemplated by this Agreement. All representations and warranties provided to the Company
or Reviva furnished by or on behalf of Investor, taken as a whole, are true and correct and do not contain any untrue statement
of material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading. Investor agrees to notify the Company and Reviva immediately upon the
occurrence of any event that would cause any representation, warranty, covenant or other statement contained in this Agreement
to be false or incorrect or of any change in any statement made herein.

 

(h) Neither Investor nor, to the extent it has them, any of its shareholders, members, managers, general or limited partners,
directors, Affiliates or executive officers (collectively with Investor, the “Covered Persons”), are
subject to any of the “Bad Actor” disqualifications described in Rule 506(d) under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). Investor has exercised reasonable
care to determine whether any Covered Person is subject to a Disqualification Event. The acquisition of Subject Shares by Investor
will not subject the Company to any Disqualification Event.

 

(i) Investor acknowledges that, in connection with the Conversion, the Company’s Ordinary Shares, including any
Subject Shares acquired by Investor, will be converted into shares of Common Stock of the Delaware successor to the Company.

 

(j) Neither the Investor nor any of its respective directors, managers, officers or owners are the subject of any U.S.
Sanctions Laws, including but not limited to any laws, regulations, executive orders, or other restrictions or prohibitions administered
by the U.S. Department of the Treasury’s Office of Foreign Assets Control (“OFAC”). Neither the
Investor nor any of its respective directors, managers, officers or owners are: (i) designated on any list of restricted parties
maintained by the U.S. Government including, but not limited to, OFAC’s Specially Designated Nationals and Blocked Persons
List, the list of Foreign Sanctions Evaders, or the Sectoral Sanctions Identifications List; the U.S. Department of Commerce’s
Denied Persons List or Entity List; or the U.S. Department of State’s Debarred List; or (ii) located, organized, resident,
or doing business in any country or territory that is, or whose government is, the subject of comprehensive territorial U.S. Sanctions
Laws, including, without limitation Crimea, Cuba, Iran, North Korea, and Syria. To the extent required, the Investor maintains
policies and procedures reasonably designed for the screening of its investors against U.S. Government restricted party lists,
including the lists herein referenced. To the extent required, it maintains policies and procedures reasonably designed to ensure
that the funds held by the undersigned and used to purchase the Subject Shares were legally derived and will be and transferred
in compliance with U.S. law.

 

    	 	5	 

     

    

 

6. Waiver Against Trust. Investor hereby represents and warrants that it has read the IPO Prospectus, and understands
that the Company has established a trust account (the “Trust Account”) containing the proceeds of its
initial public offering (the “IPO”) and the overallotment shares acquired by its underwriters and from
certain private placements occurring simultaneously with the IPO (including interest accrued from time to time thereon) for the
benefit of the Company’s public shareholders (including overallotment shares acquired by the Company’s underwriters,
the “Public Shareholders”), and that, except as otherwise described in the IPO Prospectus, the Company
may disburse monies from the Trust Account only: (a) to the Public Shareholders in the event they elect to redeem their the Company
shares in connection with the consummation of the Company’s initial business combination (as such term is used in the IPO
Prospectus) (the “Business Combination”) or in connection with an extension of its deadline to consummate
a Business Combination, (b) to the Public Shareholders if the Company fails to consummate a Business Combination within eighteen
(18) months after the closing of the IPO, which has since been extended by amendment to the Company’s organizational documents
to December 28, 2020, and is subject to further extension by additional amendments to the Company’s organizational documents,
(c) with respect to any interest earned on the amounts held in the Trust Account, amounts necessary to pay for any taxes or (d)
to the Company after or concurrently with the consummation of a Business Combination. For good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, Investor hereby agrees on behalf of itself and its Affiliates that, notwithstanding
anything to the contrary in this Agreement, neither Investor nor any of its Affiliates do now or shall at any time hereafter have
any right, title, interest or claim of any kind in or to any monies in the Trust Account or distributions therefrom, or make any
claim against the Trust Account (including any distributions therefrom), regardless of whether such claim arises as a result of,
in connection with or relating in any way to, this Agreement or any proposed or actual business relationship between Investor or
its Representatives, on the one hand, and the Company or its Representatives, on the other hand, or any other matter, and regardless
of whether such claim arises based on contract, tort, equity or any other theory of legal liability (collectively, the “Released
Claims”). Investor on behalf of itself and its Affiliates hereby irrevocably waives any Released Claims that Investor
or any of its Affiliates may have against the Trust Account (including any distributions therefrom) now or in the future as a result
of, or arising out of, any negotiations, contracts or agreements with the Company or its Representatives and will not seek recourse
against the Trust Account (including any distributions therefrom) for any reason whatsoever (including for an alleged breach of
this Agreement or any other agreement with the Company or its Affiliates). Investor intends and understands such waiver to be valid,
binding and enforceable against Investor and each of its Affiliates under applicable law. Notwithstanding the foregoing, this Section
6 shall not affect any rights of Investor or its Affiliates as a Public Shareholder to receive distributions from the Trust
Account in its capacity as a Public Shareholder (but subject to the agreements of Investor in Section 2).

 

7. Registration Rights. In the event that the Company issues any Additional Shares at the Closing, the Company
agrees that, within ninety (90) days after the Closing, it will file with the SEC (at its sole cost and expense) a registration
statement registering the resale of the Additional Shares (the “Registration Statement”), and it shall
use its commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after the
filing thereof. The Company agrees that it will cause such Registration Statement or another registration statement (which may
be a “shelf” registration statement) to remain effective until the earliest of (i) two years from the issuance of the
Additional Shares, (ii) the date on which Investor ceases to hold the Additional Shares covered by such Registration Statement
and (iii) the first date on which Investor can sell all of its Additional Shares under Rule 144 of the Securities Act without limitation
as to the manner of sale or the amount of such securities that may be sold. Investor agrees to disclose its beneficial ownership,
as determined in accordance with Rule 13d-3 of the Exchange Act, of the Additional Shares to the Company upon request to assist
the Company in making the determination described above. The Company’s obligations to include the Additional Shares in the
Registration Statement are contingent upon Investor furnishing in writing to the Company such information regarding Investor, the
securities of the Company held by Investor and the intended method of disposition of the Additional Shares as shall be reasonably
requested by the Company to effect the registration of the Additional Shares, and shall execute such documents in connection with
such registration as the Company may reasonably request that are customary of a selling stockholder in similar situations. The
Company may delay filing or suspend the use of any such registration statement if it determines that in order for the registration
statement to not contain a material misstatement or omission, an amendment thereto would be needed, or if such filing or use could
materially affect a bona fide business or financing transaction of the Company or would require premature disclosure of information
that could materially adversely affect the Company (each such circumstance, a “Suspension Event”); provided,
that the Company shall use commercially reasonable efforts to make such registration statement available for the sale by Investor
of such securities as soon as practicable thereafter. Upon receipt of any written notice from the Company of the happening of any
Suspension Event during the period that the Registration Statement is effective or if as a result of a Suspension Event the Registration
Statement or related prospectus contains any untrue statement of a material fact or omits to state any material fact required to
be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made (in the
case of the prospectus) not misleading, Investor agrees that it will (i) immediately discontinue offers and sales of the Additional
Shares under the Registration Statement until Investor receives (A) (x) copies of a supplemental or amended prospectus that corrects
the misstatement(s) or omission(s) referred to above and (y) notice that any post-effective amendment has become effective or (B)
notice from the Company that it may resume such offers and sales, and (ii) maintain the confidentiality of any information included
in such written notice delivered by the Company unless otherwise required by applicable law. If so directed by the Company, Investor
will deliver to the Company or destroy all copies of the prospectus covering the Additional Shares in Investor’s possession;
provided, however, that this obligation to deliver or destroy all copies of the prospectus covering the Additional Shares shall
not apply to (i) the extent that Investor is required to retain a copy of such prospectus (A) in order to comply with applicable
legal, regulatory, self-regulatory or professional requirements or (B) in accordance with a bona fide pre-existing document retention
policy or (ii) copies stored electronically on archival servers as a result of automatic data back-up.

 

    	 	6	 

     

    

  

8. Further Assurances. From time to time, at another party’s request and without further consideration
(but at the requesting party’s reasonable cost and expense), each party shall execute and deliver such additional documents
and take all such further action as may be reasonably necessary to consummate the transactions contemplated by this Agreement.

 

9. Expenses. Each party hereto shall pay all of its own expenses in connection with this Agreement and the transactions
contemplated hereby.

 

10. Information; Confidentiality. Without limiting any pre-existing confidentiality obligations of Investor, Investor
agrees that it will not, until the Closing, without the Company’s prior written consent, disclose to any other person or
entity the nature, extent or fact that Investor is entering this Agreement or the terms and conditions hereof, or any information
Investor may receive in connection with this Agreement (in each case to the extent the Company or its Representatives have communicated
the confidentiality thereof) other than (a) pursuant to the order of any court or administrative agency or in any pending legal
or administrative proceeding, or otherwise as required by applicable law or compulsory legal process (in which case Investor agrees,
to the extent not prohibited by applicable law, to inform the Company promptly thereof prior to such disclosure and cooperate with
any efforts by the Company to prevent or limit such disclosure), (b) to the extent that such information is or becomes publicly
available other than by reason of disclosure by Investor or its Representatives in violation of this Agreement, or (c) to Investor’s
Representatives who need to know such information and who are informed of the confidential nature of such information and are obligated
to keep such information confidential. Investor will cause its Representatives to comply with the confidentiality provisions of
this Agreement as fully as if they were a party hereto and will be responsible for a breach of the confidentiality provisions of
this Agreement by any such Representatives. In addition, Investor shall not, for a period of six (6) months from the date hereof,
make any public disclosure of the nature, extent or fact that Investor is entering this Agreement or the terms and conditions hereof,
without the prior written consent of the Company. Notwithstanding the foregoing, Investor acknowledges that the Company may file
a copy of this Agreement, along with a summary thereof, with the SEC.

 

11. Term. This Agreement and each party’s obligations hereunder shall terminate upon (a) the mutual written
consent of the Company, Investor and Reviva or (b) the termination of the Merger Agreement in accordance with its terms; provided,
that: (i) no termination of this Agreement will affect the liability of a party for any breach of this Agreement prior to termination;
(ii) the provisions of Sections 6 and 9 through 20 of this Agreement will survive any termination of this
Agreement and continue indefinitely, and (iii) the termination of this Agreement will not affect any confidentiality obligations
of Investor to the Company or Reviva pursuant to any confidentiality agreements entered into by Investor prior to the date hereof.

 

    	 	7	 

     

    

 

12. Notices. All notices, consents, waivers and other communications hereunder will be in writing and will be
deemed to have been duly given when delivered (i) in person, (ii) by facsimile or other electronic means, with affirmative confirmation
of receipt, (iii) one (1) Business Day after being sent, if sent by reputable, nationally recognized overnight courier service
or (iv) three (3) Business Days after being mailed, if sent by registered or certified mail, pre-paid and return receipt requested,
in each case to the applicable party at the following addresses (or at such other address as shall be specified by like notice):

 

	
        If to the Company at or prior to the Closing, to:

         

        Tenzing Acquisition Corp.

        250 W. 55th St., Suite 13D

        New York, NY 10019

        Attn: Rahul Nayar, CEO

        Telephone No.: (212) 710-5220

        Email: rnayar@shreecap.com
	
        with a copy (which will not constitute notice) to:

         

        Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas, 11th Floor

New York, New York 10105, USA

Attn:Barry I. Grossman, Esq.

           Matthew A. Gray, Esq.

Facsimile No.: (212) 370-7889

Telephone No.: (212) 370-1300

Email:bigrossman@egsllp.com

            mgray@egsllp.com 

	
        If to Reviva prior to the Closing, to:

         

        Reviva Pharmaceuticals, Inc.

        19925 Stevens Creek Blvd., Suite 100

        Cupertino, CA 95014

        Attn: Laxminarayan Bhat

        Facsimile No.: (408) 904.6270

        Telephone No.: (408) 501-8881

        Email: lbhat@revivapharma.com

         
	
        with a copy (which will not constitute notice) to:

         

        Lowenstein Sandler LLP

        One Lowenstein Drive

        Roseland, New Jersey 07068

        Attn: Steven M. Skolnick, Esq.

        Facsimile No.: (973) 597-2477

        Telephone No.: (973) 597-2476

        Email: sskolnick@lowenstein.com

         

	
        If to the Company or Reviva after the Closing, to:

         

        Reviva Pharmaceuticals Holdings, Inc.

        19925 Stevens Creek Blvd., Suite 100

        Cupertino, CA 95014

        Attn: Laxminarayan Bhat

        Facsimile No.: (408) 904.6270

        Telephone No.: (408) 501-8881

        Email: lbhat@revivapharma.com

         
	
        with a copy (which will not constitute notice) to:

         

        Lowenstein Sandler LLP

        One Lowenstein Drive

        Roseland, New Jersey 07068

        Attn: Steven M. Skolnick, Esq.

        Facsimile No.: (973) 597-2477

        Telephone No.: (973) 597-2476

        Email: sskolnick@lowenstein.com

         

        and

         

        Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas, 11th Floor

New York, New York 10105, USA

Attn:Barry I. Grossman, Esq.

           Matthew A. Gray, Esq.

Facsimile No.: (212) 370-7889

Telephone No.: (212) 370-1300

Email:bigrossman@egsllp.com

            mgray@egsllp.com 

 

    	 	8	 

     

    

 

	
        If to the Investor, to:

         

        Name: [___________________________________]

Address: [__________________________________]

[__________________________________________]

Attn: [______________]

Facsimile No.: [___________________]

Telephone No.: [____________________]

Email: [____________________________] 
	 

 

13. Entire Agreement; Amendments; Waiver. This Agreement, together with the exhibits hereto, constitutes the entire
agreement of Investor, the Company and Reviva relating to the matters contained herein and therein, superseding all prior contracts
or agreements, whether oral or written; provided, that the foregoing will not affect any confidentiality obligations of Investor
to the Company or Reviva pursuant to any confidentiality agreements entered into by Investor prior to the date hereof. This Agreement
may not be amended, modified or terminated except by an instrument in writing signed by the Company, Reviva and Investor. This
Agreement may not be waived except by an instrument in writing signed by the party against whom enforcement of waiver is sought.

 

14. Assignment; Binding Effect. This Agreement shall not be assigned without the prior written consent of the
Company, Reviva and Investor (not to be unreasonably withheld, delayed or conditioned), and any assignment without such consent
shall be null and void ab initio. Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit
of the parties and their heirs, successors and assigns, and the agreements, representations, warranties and acknowledgments contained
herein shall be deemed to be made by and be binding upon such heirs, executors, administrators, successors, legal representatives
and assigns. This Agreement does not confer any rights or remedies upon any person or entity other than the parties hereto and
their heirs, successors and permitted assigns.

 

15. Governing Law; Jurisdiction; WAIVER OF JURY TRIAL. This Agreement shall be governed by, and construed in accordance
with, the laws of the State of New York, without regard to principles relating to conflict of laws. Each party hereby irrevocably
and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the state and federal courts seated
in New York County, New York (and any appellate courts thereof) in any action or proceeding arising out of or relating to this
Agreement, and each of the parties hereby irrevocably and unconditionally (a) agrees not to commence any such action or proceeding
except in such courts, (b) agrees that any claim in respect of any such action or proceeding may be heard and determined in such
court, (c) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have
to the laying of venue of any such action or proceeding in any such court, and (d) waives, to the fullest extent permitted by law,
the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. Each party agrees that
a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by law. Each party irrevocably consents to the service of the summons and complaint and
any other process in any other Proceeding relating to the transactions contemplated by this Agreement, on behalf of itself, or
its property, by personal delivery of copies of such process to such party at the applicable address set forth in Section 12.
Nothing in this Section 15 shall affect the right of any party to serve legal process in any other manner permitted by law.
Each party hereby knowingly, voluntarily and intentionally irrevocably waives the right
to a trial by jury in respect to any litigation, dispute, claim, legal action or other legal proceeding based hereon, or arising
out of, under, or in connection with, this Agreement.

 

    	 	9	 

     

    

 

16. Specific Performance. Each party acknowledges that the rights of each party to consummate the transactions
contemplated by this Agreement are unique, recognizes and affirms that in the event of a breach of this Agreement by any party,
money damages may be inadequate and the non-breaching party may have not adequate remedy at law, and agree that irreparable damage
would occur in the event that any of the provisions of this Agreement were not performed by an applicable party in accordance with
their specific terms or were otherwise breached. Accordingly, each party shall be entitled to seek an injunction or restraining
order to prevent breaches of this Agreement and to seek to enforce specifically the terms and provisions hereof, without the requirement
to post any bond or other security or to prove that money damages would be inadequate, this being in addition to any other right
or remedy to which such party may be entitled under this Agreement, at law or in equity.

 

17. Severability. In case any provision in this Agreement shall be held invalid, illegal or unenforceable in a
jurisdiction, such provision shall be modified or deleted, as to the jurisdiction involved, only to the extent necessary to render
the same valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions hereof shall not
in any way be affected or impaired thereby nor shall the validity, legality or enforceability of such provision be affected thereby
in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced,
the parties will substitute for any invalid, illegal or unenforceable provision a suitable and equitable provision that carries
out, so far as may be valid, legal and enforceable, the intent and purpose of such invalid, illegal or unenforceable provision.

 

18. Certain Definitions. For the purposes of this Agreement, the following capitalized terms have the following
meanings:

 

(a) “Affiliate” means affiliate as such term is defined in Rule 12b-2 under the Exchange Act
(for the avoidance of doubt, any reference in this Agreement to an Affiliate of the Company prior to the Business Combination will
include the Sponsor).

 

(b) “Business Day” means any day other than a Saturday, Sunday or other day on which banks
in New York, New York are authorized or required by law to be closed, excluding as a result of “stay at home”, “shelter-in-place”,
 “non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations
at the direction of any governmental authority so long as the electronic funds transfer systems, including for wire transfers,
of commercially banking institutions in New York, New York are generally open for use by customers on such day.

 

(c) “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.

 

(d) “Redemption Price” means an amount equal to the price at which each Ordinary Share (or
after the Conversion, each share of Common Stock) is redeemed or converted pursuant to the Closing Redemption.

 

(e) “Representatives” means, with respect to any party, its Affiliates and the respective officers,
directors, managers, employees, consultants, advisors, agents and other legal representatives of such party and its Affiliates.

 

(f) “Securities Act” means the U.S. Securities Act of 1933, as amended.

 

    	 	10	 

     

    

 

19. Interpretation. The headings, titles and subtitles used in this Agreement are for convenience only and are
not to be considered in construing or interpreting this Agreement. In this Agreement, unless the context otherwise requires: (i)
any pronoun used shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns, pronouns
and verbs shall include the plural and vice versa; (ii) “including” (and with correlative meaning “include”)
means including without limiting the generality of any description preceding or succeeding such term and shall be deemed in each
case to be followed by the words “without limitation”; (iii) the words “herein,” “hereto,”
and “hereby” and other words of similar import shall be deemed in each case to refer to this Agreement as a whole and
not to any particular section or other subdivision of this Agreement; and (iv) the term “Dollars” or “$”
means U.S. dollars. The parties have participated jointly in the negotiation and drafting of this Agreement. Consequently, in the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the
parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provision of this Agreement.

 

20. Counterparts; Facsimile. This Agreement may be executed in any number of counterparts, each of which when
so executed and delivered shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.
A facsimile or other electronic transmission of this signed Agreement shall be legal and binding on all parties hereto.

 

{Signature page follows}

 

    	 	11	 

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement, as of the date first written above.

 

	 	The Company:
	 	 
	 	TENZING ACQUISITION CORP.
	 	 	 	 
	 	By:	      
	 	 	Name:  	Rahul Nayar
	 	 	Title:  	 Chief Executive Officer
	 	 	 	 
	 	 	 	 
	 	Reviva:
	 	 
	 	REVIVA PHARMACEUTICALS, INC.
	 	 	 	 
	 	By:	     
	 	 	Name:  	Laxminarayan Bhat
	 	 	Title:  	Founder, President and CEO
	 	 	 	 
	 	 	 	 
	 	Investor:
	 	 	 	 
	 	[________________________________________]
	 	 	 	 
	 	By:	     
	 	 	Name:	 
	 	 	Title:	 

  

 

{Signature Page to Backstop Agreement}

 

    	 	 	 

     

    

 

Exhibit A

Investor Questionnaire

 

THIS QUESTIONNAIRE MUST BE ANSWERED FULLY
AND RETURNED ALONG WITH YOUR COMPLETED BACKSTOP AGREEMENT IN CONNECTION WITH YOUR PROSPECTIVE PURCHASE OF ORDINARY SHARES FROM
THE COMPANY.

 

THE INFORMATION SUPPLIED IN THIS QUESTIONNAIRE
WILL BE HELD IN STRICT CONFIDENCE. NO INFORMATION WILL BE DISCLOSED EXCEPT TO THE EXTENT THAT SUCH DISCLOSURE IS REQUIRED BY LAW
OR REGULATION, OTHERWISE DEMANDED BY PROPER LEGAL PROCESS OR IN LITIGATION INVOLVING THE COMPANY, REVIVA OR THEIR RESPECTIVE CONTROLLING
PERSONS.

 

Capitalized terms used herein without definition
shall have the respective meanings given such terms as set forth in the Backstop Agreement by and among Tenzing Acquisition Corp.,
a company incorporated in the British Virgin Islands (together with its successors, the “Company”), Reviva
Pharmaceuticals, Inc., a Delaware corporation (together with its successors, “Reviva”), and [_______________________]
(“Investor”).

 

(1) The
undersigned Investor represents and warrants that he, she or it comes within at least one category marked below, and that for any
category marked, he, she or it has truthfully set forth, where applicable, the factual basis or reason the undersigned comes within
that category. The undersigned agrees to furnish any additional information which the Company reasonably deems necessary in order
to verify the answers set forth below.

 

	Category A ___	
        The undersigned is an individual (not a
        partnership, corporation, etc.) whose individual net worth, or joint net worth with his or her spouse, presently exceeds $1,000,000.

         

        Explanation. In calculating
net worth, you include all of your assets (other than your primary residence), whether liquid or illiquid, such as cash, stock,
securities, personal property and real estate based on the fair market value of such property MINUS all debts and liabilities
(except that a mortgage or other debt secured by your primary residence, up to the estimated fair market value of the primary
residence as of the Closing, shall not be included as a liability, provided that if the amount of such indebtedness outstanding
as of the Closing exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of your
primary residence, the amount of such excess shall be included as a liability. Further, the amount of any mortgage or other indebtedness
secured by your primary residence that exceeds the fair market value of the residence as of the Closing shall be included as a
liability. 

 

	Category B ___	The undersigned is an individual (not a partnership, corporation, etc.) who had an income in excess of $200,000 in each of the two most recent years, or joint income with his or her spouse in excess of $300,000 in each of those years (in each case including foreign income, tax exempt income and full amount of capital gains and losses but excluding any income of other family members and any unrealized capital appreciation) and has a reasonable expectation of reaching the same income level in the current year.

 

	Category C ___	The undersigned is a director or executive officer of the Company.

 

    	 	A-1	 

     

    

 

	Category D ___	
        The undersigned is a bank, as
defined in Section 3(a)(2) of the Securities Act of 1933, as amended (the “Act”); a savings and loan association
or other institution as defined in Section 3(a)(5)(A) of the Act, whether acting in its individual or fiduciary capacity;
any broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934; any insurance company as defined
in Section 2(a)(13) of the Act; any investment company registered under the Investment Company Act of 1940 or a business
development company as defined in Section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small
Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and
maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions,
for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the
meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined
in Section 3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment
advisor, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment
decisions made solely by persons that are accredited investors (describe entity).

___________________________________________________________________

___________________________________________________________________

 

	Category E ___	
        The undersigned is a private business
development company as defined in Section 202(a) (22) of the Investment Advisors Act of 1940 (describe entity) 

___________________________________________________________________

___________________________________________________________________

 

	Category F ___	
        The undersigned is either a corporation,
partnership, Massachusetts or similar business trust, or any organization described in Section 501(c)(3) of the Internal
Revenue Code, in each case not formed for the specific purpose of acquiring the Additional Shares and with total assets in excess
of $5,000,000. (describe entity)

___________________________________________________________________

___________________________________________________________________

 

	Category G ___	
        The undersigned is a trust with
total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Additional Shares, where the purchase
is directed by a “sophisticated investor” as defined in Regulation 506(b)(2)(ii) under the Act.

___________________________________________________________________

___________________________________________________________________

 

	Category H ___	
        The undersigned is an entity (other
than a trust) in which all of the equity owners are “accredited investors” within one or more of the above categories.
If relying upon this Category alone, each equity owner must complete a separate copy of this Investor Questionnaire. (describe
entity)

 

___________________________________________________________________

___________________________________________________________________

 

	 	The undersigned agrees that the undersigned will notify the Company at any time on or prior to the applicable closing in the event that the representations and warranties in this Investor Questionnaire shall cease to be true, accurate and complete.

 

    	 	A-2	 

     

    

 

(2) Suitability (please
answer each question)

 

	 	(a)	Are you familiar with the risk aspects and the non-liquidity of investments such as the Additional Shares for which you seek to acquire?

 

YES _____     NO
_____

 

	 	(b)	Do you understand that there is no guarantee of financial return on this investment and that you run the risk of losing your entire investment?

 

YES _____     NO
_____

 

(3) Manner
in which title is to be held: (circle one)

	 	(a)	Individual Ownership
	 	(b)	Community Property
	 	(c)	Joint Tenant with Right of Survivorship (both parties must sign)
	 	(d)	Partnership
	 	(e)	Tenants in Common
	 	(f)	Company
	 	(g)	Trust
	 	(h)	Other

 

(4) Are you a U.S.
person (as defined in the Securities Act)?

 

YES _____     NO
_____

 

(5) FINRA Affiliation.

 

Are
you affiliated or associated with a member of FINRA (please check one):

 

YES _____     NO
_____

 

If Yes, please describe: 

_______________________________________________________________________________

_______________________________________________________________________________

_______________________________________________________________________________

 

*If subscriber is a Registered
Representative with a member of FINRA, have the following acknowledgment signed by the appropriate party:

  

The undersigned FINRA firm acknowledges
receipt of the notice required by the Conduct Rules of FINRA.

  

	 	 	 	 
	 	Name of NASD Member Firm	 	 
	 	 	 	 
	 	By:	 	 	 
	 	 	Authorized Officer	 	 
	 	 	 	 	 
	 	Date:	 	 	 

 

{Remainder of page intentionally left
blank}

 

    	 	A-3	 

     

    

 

The undersigned Investor
is informed of the significance to the Company and Reviva of the foregoing representations and answers contained in this Investor
Questionnaire and such answers have been provided under the assumption that the Company and Reviva will rely on them. The undersigned
Investor represents and warrants to the Company and Reviva that the information in this Investor Questionnaire is true, complete
and accurate and may be relied upon by the Company and Reviva. The undersigned Investor understands that a false representation
may constitute a violation of law, and that any person or entity who suffers damage as a result of a false representation may have
a claim against Investor for damages.

 

 

 

	 	[_________________________________]
	 	 	 
	 	By: 	 
	 	 	Name:	            
	 	 	Title:	 
	 	 	 	 
	 	 	Date:	 

  

    	 	A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]